Clinical trials: Peripheral Arterial Obstructive Disease
Peripheral Arterial Disease
IN.PACT Global Clinical Study
The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiral™ Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries in a "real world"…
- Trial name
- NCT01609296
- Testing
- IN.PACT Admiral™ Drug Eluting Balloon
- Where
- 65 sites in Argentina, Australia and 25 more
- Volunteers
- 1,535 people
- Sponsor
- Medtronic Endovascular
Peripheral Artery Disease
BIOTRONIK Dynetic-35 Stent for the Treatment of Peripheral Iliac Lesions
BIOTRONIK cobalt chromium balloon-expandable Dynetic-35 stent in association with Passeo-35 Xeo peripheral dilation catheter for the treatment of peripheral iliac lesions
- Trial name
- BIONETIC-I (NCT04830228)
- Testing
- Ballon expandable stent and PTA
- Where
- 15 sites in Austria, Belgium and 4 more
- Volunteers
- 160 people
- Sponsor
- Biotronik AG
Critical Limb Ischemia (CLI)
Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects…
- Trial name
- NCT03006770
- Testing
- PLX-PAD
- Where
- 57 sites in United States, Bulgaria and 7 more
- Volunteers
- 213 people
- Sponsor
- Pluristem Ltd.
Peripheral Artery Disease
BRight Pharmacokinetic Study
The BRight PK Study is a prospective, single-arm, open-label, non-blinded, non-randomized study, which goal is to assess the pharmacokinetic profile of the BRight drug-coated balloon at different time points after the balloon…
- Trial name
- NCT06065345
- Testing
- BRight DCB
- Where
- Australia
- Volunteers
- 6 people
- Sponsor
- Biotronik CRC Inc.
Peripheral Artery Disease
Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries
Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions…
- Trial name
- NCT02278991
- Testing
- Lutonix Drug Coated Balloon
- Where
- 12 sites in Germany, Greece and 1 more
- Volunteers
- 149 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese
The main objective is to evaluate the effect of single dose Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese…
- Trial name
- NCT02786069
- Testing
- Propionyl L-carnitine Hydrochloride
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Peripheral Arterial Disease
DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes
This is a prospective, multi-center, observational registry to document the baseline, 24-hour and 30-day inflammatory response and procedural outcomes out to 12 month follow-up after femoropopliteal angioplasty or…
- Trial name
- NCT02469532
- Testing
- Balloon Angioplasty, Atherectomy System
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mercator MedSystems, Inc.
Peripheral Vascular Disease
Endovascular Atherectomy Safety and Effectiveness Study
The purpose of this study is to evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries.
- Trial name
- EASE (NCT01541774)
- Testing
- Phoenix Atherectomy System
- Where
- 16 sites in United States, Germany
- Volunteers
- 128 people
- Sponsor
- AtheroMed, Inc
Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD)
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Post-Market Clinical Follow-Up (PMCF) Observational Registry (RE-PROVE)
Collect real-world post-market clinical follow-up data on subjects treated with the Reduced Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (Reduced Profile VBX Stent Graft-BXB)
- Conditions
- Aorto-iliac Occlusive Disease (AIOD), Visceral Artery Occlusive Disease (VAOD), Isolated Artery Aneurysms (IAA), Trauma or Iatrogenic Vessel Injury
- Trial name
- NCT07279649
- Testing
- Reduced Profile GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (Reduced Profile VBX Stent Graft-BXB)
- Where
- Germany
- Volunteers
- 240 people
- Sponsor
- W.L.Gore & Associates
Peripheral Arterial Diseases
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically…
- Trial name
- DANCE (NCT01983449)
- Testing
- Dexamethasone Sodium Phosphate Injection, USP
- Where
- 38 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mercator MedSystems, Inc.
Arterial Occlusive Disease, Peripheral Vascular Disease
Study of HGF Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia
The primary purpose of this study was to assess the overall safety of different dose regimens of AMG0001 (HGF transferred via plasmid vector) as well as evaluate the improvement of blood perfusion in subjects with critical limb…
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia
- Trial name
- NCT00060892
- Testing
- HGF plasmid
- Where
- 24 sites in United States
- Volunteers
- 104 people
- Sponsor
- AnGes USA, Inc.
Peripheral Artery Disease
FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease
The primary objective of this prospective, Randomized, Controlled, Multicentre, Open Study is to investigate the inhibition of restenosis by the Paclitaxel-eluting Percutaneous transluminal angioplasty (PTA) balloon Freeway…
- Trial name
- NCT01960647
- Testing
- Percutaneous transluminal angioplasty with uncoated balloon, Percutaneous transluminal angioplasty with Paclitaxel balloon
- Where
- 17 sites in Austria, Colombia and 4 more
- Volunteers
- 280 people
- Sponsor
- Eurocor GmbH
Peripheral Arterial Disease
Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease
Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) has been widely used as an anti-platelet agent for the treatment of PAD.
- Trial name
- NCT03318276
- Testing
- SID142, Rinexin® Tab
- Where
- South Korea
- Volunteers
- 170 people
- Sponsor
- SK Chemicals Co., Ltd.
Critical Limb Ischemia
Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia
The purpose of this study is to investigate the efficacy and safety of autologous transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with critical limb ischemia
- Trial name
- NCT01663376
- Testing
- Autologous Adipose Tissue derived MSCs Transplantation
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- R-Bio
Peripheral Arterial Disease (PAD)
An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs
This is an observational study in which data already collected from people with peripheral arterial diseases (PAD) who had a surgery to improve blood flow to their legs are studied.
- Trial name
- NCT07142655
- Where
- Japan
- Volunteers
- 1,500 people
- Sponsor
- Bayer
Peripheral Arterial Disease, Peripheral Vascular Disease
Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD
The purpose of this study is to assess the safety and efficacy of a novel, tissue-engineered vascular prosthesis, the Human Acellular Vessel (HAV).
- Trial name
- NCT01872208
- Testing
- HAV implantation
- Where
- 3 sites in Poland
- Volunteers
- 20 people
- Sponsor
- Humacyte, Inc.
Peripheral Arterial Disease
The ILLUMINA Study. (ILLUMINA)
The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite event-free survival rate up to two years…
- Trial name
- ILLUMINA (NCT03510676)
- Testing
- NiTiDES
- Where
- 10 sites in France, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- CID - Carbostent & Implantable Devices
Coronary Artery Disease, Cerebrovascular Disease
RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease
The objective of this study is to evaluate an antibiotic therapy called Rifalazil to determine its effect on hardening of the carotid arteries.
- Conditions
- Coronary Artery Disease, Cerebrovascular Disease, Peripheral Vascular Disease
- Trial name
- NCT00385385
- Testing
- Rifalazil
- Where
- 6 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- ActivBiotics
Peripheral Artery Disease
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
- Trial name
- SUCCESS PTA (NCT04776434)
- Testing
- SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
- Where
- 27 sites in Argentina, Germany and 6 more
- Volunteers
- 723 people
- Sponsor
- M.A. Med Alliance S.A.
Peripheral Artery Disease, Vascular Disease
In-Stent Restenosis Post-Approval Study
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
- Trial name
- NCT02542267
- Testing
- Gore VIABAHN Endoprosthesis
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 108 people
- Sponsor
- W.L.Gore & Associates